Merck KGaA to Open $326 Million Pharmaceutical Plant in South Korea to Expand in Asia
By David Sachs
Merck KGaA will spend more than 300 million euros ($326 million) on a pharmaceutical plant in South Korea as part of its strategy to expand in Asia.
The German drug-and-chemicals company said Wednesday that the plant will add 300 jobs. The Daejeon facility will serve biotech and pharmaceutical companies that develop, research and manufacture medical treatments like vaccines and cell, gene, and protein-based therapies, Merck said.
The production site will bring the firm closer to customers in an expanding market and should speed up the process of bringing new treatments from the development phase to commercialization, the firm said. Merck's investment is the largest to date by its life-sciences division in the Asia-Pacific region.
Write to David Sachs at david.sachs@wsj.com
(END) Dow Jones Newswires
March 20, 2024 11:42 ET (15:42 GMT)
Copyright (c) 2024 Dow Jones & Company, Inc.-
4 Predictions for Stocks and the Economy for the Second Half of 2024
-
What Broadening Rally? AI Stocks Dominate Again In Q2
-
After Earnings, Is Nike Stock a Buy, a Sell, or Fairly Valued?
-
Worst-Performing Stock ETFs of the Quarter
-
Top-Performing Stock ETFs of the Quarter
-
Q2 In Review and Q3 2024 Market Outlook
-
5 Stocks to Buy for 3Q 2024
-
Best- and Worst-Performing Stocks of Q2 2024
-
Industrials: Sector Offers Investment Opportunities as Performance Lags Broader Market
-
Consumer Defensives: Even Amid Macro Pressures, Deals Permeate the Landscape
-
33 Undervalued Stocks
-
Utilities: Can the Stocks Keep the Rally Going?
-
Basic Materials: Following Index Decline, We See Many Long-Term Opportunities
-
Healthcare: Valuations Look Attractive In Most Industries
-
Financial Services: Amid Uncertainties, We See the Most Value In Banks and Credit Services
-
Consumer Cyclicals: Even With Anxiety Over Spending, We See Attractive Valuations